Skip to content

Mepilex Border Flex Utilization Pilot Spain

Observational Study to Describe the Utilization of Foam Dressings in Routine Clinical Practice, for the Treatment of Patients With Chronic Wounds in Primary Healthcare Centers in Spain.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06321978
Acronym
MxBFlexUPESP
Enrollment
40
Registered
2024-03-20
Start date
2024-02-16
Completion date
2024-05-31
Last updated
2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound

Brief summary

The aim of this study is to assess and describe the utilization of Mepilex® Border Flex and other foam dressings available in routine clinical practice in the management of patients with chronic wounds, in order to understand the pattern of use and the frequency of dressing changes in wound management. The study will also allow to gain information about the opinion of the HCPs and the patient's experience concerning wound management with foam dressings. This information may help to understand patient's health care optimization in terms of quality and efficiency.

Interventions

DEVICEMepilex Border Flex

Usage of Mepilex Border Flex according to intended use and standard of care.

Sponsors

Molnlycke Health Care AB
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years or older. * The patient has been deemed by the HCP to change dressing to Mepilex® Border Flex. * Patients with chronic wounds (wounds that have not reduced in size by more than 40% to 50% or healed within a month) treated with foam dressings, other that Mepilex® Border Flex, according to its intended use at baseline visit for minimum 4 weeks. * Patients with an expectation of wound follow-up of at least 4 weeks. * Patients agree only to have the dressing changed by the HCP. * Patients capable of signing the Informed Consent Form and answer the questions being asked.

Exclusion criteria

* Patients with any applicable contraindication or sensibilization to any of the dressing compounds * Patients with pressure ulcers (PU) stage I, deep tissue injuries or terminal wounds (e.g., fungating wounds) * Patients with wounds whose location and/or aetiology requires a dressing change for reasons that are unrelated to the dressing characteristics such as wounds in the sacral area. * Hospice patients * Patients participating in other studies interfering with this study.

Design outcomes

Primary

MeasureTime frameDescription
Dressing use4 weeksNumber of dressings used the week before baseline visit compared to the number of dressings used the week before follow-up visit.

Secondary

MeasureTime frameDescription
Wound characteristics4 weeksDescribe clinical characteristics of chronic wounds that are treated with foam dressings in routine clinical practice by HCP assessment
Wound management4 weeksDescribe the management of chronic wounds in terms of frequency of dressing change, type of dressings used and reason for dressing change
Technical Performance (HCP evaluation)4 weeksSeveral questions will be asked to evaluate the technical performance properties of the primary dressing. The following will be assessed by the investigator/designee using no/yes values: 1\) Based on this patient, would you recommend Mepilex Border Flex for use in your organisation? All other properties will be assessed by the investigator/designee using a 3-item scale of worse, same, better. These include: * Ease of application * Ease of removal * Ability to conform to wound site * Ability to indicate the need for dressing change * Ability to stay in place * Trauma to the wound bed * Ability to indicate the need for dressing change * Trauma to the wound bed * Trauma to the peri-wound skin * Patient concordance * Overall dressing performance
Patient Experience (PRO)4 weeksPatients are asked to rate the dressings in regards their experience The following questions will be assessed by the investigator/designee using a 1-10 level visual analogue scale for pain: * How wound you rate the pain in your wound today? * How would you rate the pain when Mepilex Border Flex was removed from your wound today? The following will be assessed by the investigator/designee using no/yes values: \*Would you recommend this treatment to a relative or friend? All other properties will be assessed by the investigator/designee using a 4-item scale of very poor, poor, good, very good. These include: * How would you rate the comfort of Mepilex Border Flex applied to your wound? * How would you rate Mepilex Border Flex used in regards to the ability to stay in place? * How would you rate your overall satisfaction regarding wound management (including the properties of Mepilex Border Flex and treatment of your wound)
Costs4 weeksEstimate the weekly cost per patient associated with the dressings used in wound care episodes and the characteristics of use by evaluating type and size of wound and frequency of dressing change

Countries

Spain

Contacts

Primary ContactFia Navntoft
fia.navntoft@molnlycke.com+46 31-722 30 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026